Our lab is getting a major upgrade!! 🧬👩🏽‍🔬 😅 #personalizedmedicine #oncology #clia

The new QuadCast from our #ACROpolis partners QuadShot News highlights PROSTOX's ability to predict late GU toxicity, why long course chemoradiation may be better than short course RT in rectal cancer, & aggressive chromosomal alterations in meningiomas: podcasts.apple.com/us/podcast/4-2…

🚨Just announced: MiraDx & UCLA research to be presented at #ASCO25! Findings show MiraDx’s mirSNP platform predicts response & toxicity risk in two very different treatment settings—radiation and immunotherapy. miradx.com/new-research-u… #oncology #immunotherapy #radiationtherapy

🚨 Catch us at #ASCO25! Dr. Joanne Weidhaas, in collaboration with UCLA, is presenting 2 posters on microRNA signatures that predict cancer treatment toxicity: 📍 May 31, 9 AM – Radiation therapy 📍 June 2, 1:30 PM – Immunotherapy & irAEs #microRNA #CancerResearch #miradx

Heading to #ASCO25? See how microRNA biomarkers can personalize RT for STS: 📍 Poster: May 31, 9 AM | Hall A | Abstract 11538 | Poster Bd 21 🧬 Predicts wound toxicity & distant failure 🧬 Informs SBRT vs. standard RT 🎤 Chat with Dr. Joanne Weidhaas. #Sarcoma #miradx

Showcasing new microRNA-based research on predicting cancer treatment toxicity at #ASCO25: 📌 Radiation therapy in sarcomas | May 31, 9 AM 📌 irAEs to anti-PD1 immunotherapy | June 2, 1:30 PM #miradx #CancerResearch

Happening today at #ASCO25! Stop by Hall A at 9 AM: MicroRNA biomarkers in STS: Abstract 11538 | Poster Bd 21 Predicting RT toxicity & response Guiding SBRT vs. standard therapy Dr. Joanne Weidhaas on the future of personalized RT. #Sarcoma

In action at #ASCO25 Dr. Joanne Weidhaas shares how germline microRNA biomarkers can guide RT decisions in soft tissue #sarcoma. 📍 Visit Hall A | Abstract 11538 | Poster Bd 21 to explore models predicting wound toxicity, distant failure, & more. #PrecisionOncology #miradx

Love seeing these great discussions at #ASCO25! Dr. Joanne Weidhaas shares insights on microRNA biomarkers that predict toxicity and other outcomes of preoperative SBRT in STS. 📍 Hall A | Abstract 11538 | Poster Bd 21– come by today! #miradx #RadiationOncology #CancerResearch

Attending #ASCO25? Don’t miss predicting immunotherapy toxicity using microRNA signatures: 🔬 Early irAEs, predictive models & genomic tools for safer treatment 📅 June 2, 1:30 PM | Hall A Poster Session 🎤 Meet Dr. Joanne Weidhaas! #Immunotherapy #Oncology #miradx

It’s #ASCO25! Join us at 1:30 PM: Predicting immunotherapy toxicity with microRNA signatures. 📍 Hall A | Abstract 2661 | Poster Bd 308 🔬 Early irAEs, predictive models & personalized genomic tools for safer treatment. 🎤 Meet Dr. Joanne Weidhaas! #Immunotherapy #miradx

Dr. Joanne Weidhaas engaging with attendees at #ASCO25! Discussing microRNA-based approach to predicting immunotherapy toxicity. #Oncology #Immunotherapy #Genomics #ASCO2025 #miradx

Dr. Joanne Weidhaas in action at #ASCO25, diving into discussions on predicting immunotherapy toxicity. Exciting to share this research and learn from others in the field! #Oncology #Genomics #Immunotherapy #ASCO2025 #miradx

Live from #ASCO25: Dr. Joanne Weidhaas sharing the latest research on predicting irAEs from anti-PD1 therapy with attendees. Stop by! #Immunotherapy #Oncology #ASCO2025 #CancerResearch #miradx

🚨 Wrapping up an incredible #ASCO25! Honored to showcase microRNA-based research to predict toxicity from: 🧬 RT in STS 🧬 Anti-PD1 Therapy Grateful to connect with so many passionate professionals—onward in advancing precision oncology! #miradx #CancerResearch #sarcoma #irAEs

Just days until #ASTRO2025! Dr. Joanne Weidhaas of UCLA Health will be presenting a poster: Treatment Choices and Toxicity Outcomes in Patients with a High Risk PROSTOX Score 📅 Sept 30 | 12:45–2:00 PM PT 📍 Hall F | PQA 07 #ProstateCancer #RadiationOncology #PROSTOX

MiraDx’s ASTRO 2025 breakthrough: Can PROSTOX ultra finally make radiation therapy safer for prostate cancer patients? business-news-today.com/miradxs-astro-… #ASTRO2025 #ProstateCancer #RadiationOncology #PrecisionMedicine #CancerDiagnostics

Happening today at #ASTRO2025: Dr. Joanne Weidhaas (UCLA Health) presents new research on how PROSTOX™ genetic testing can personalize prostate cancer treatment and reduce late GU toxicity. 📍 Hall F | 12:45–2:00 PM PT #RadiationOncology #ProstateCancer #PrecisionMedicine

That’s a wrap on #ASTRO2025! Incredible to connect with so many leaders in radiation oncology. We had great conversations, interest at the PROSTOX poster, and an inspiring few days of innovation and collaboration. #UCLAHealth #RadOnc #ProstateCancer #PROSTOX